EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for EGFR-mutation-positive advanced NSCLC and are categorized into three generations: first-generation (Gefitinib and Erlotinib), second-generation (Afatinib and Dacomitinib), and third-generation (Osimertinib) [4].